MIUDELLA Drug Patent Profile

When do Miudella patents expire, and what generic alternatives are available?

Miudella is a drug marketed by Sebela Womens Hlth and is included in one NDA. There are thirteen patents protecting this drug.

This drug has thirty patent family members in seven countries.

The generic ingredient in MIUDELLA is copper. There are fifteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the copper profile page.

DrugPatentWatch^® Generic Entry Outlook for Miudella

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 16, 2034. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for MIUDELLA

International Patents:	30
US Patents:	13
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in MIUDELLA?	MIUDELLA excipients list
DailyMed Link:	MIUDELLA at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for MIUDELLA

NDA:

218201

Dosage:

SYSTEM;INTRAUTERINE

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for MIUDELLA

Drug Class	Copper-containing Intrauterine Device
Physiological Effect	Decreased Embryonic Implantation Decreased Sperm Motility Inhibit Ovum Fertilization

US Patents and Regulatory Information for MIUDELLA

MIUDELLA is protected by thirteen US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sebela Womens Hlth	MIUDELLA	copper	SYSTEM;INTRAUTERINE	218201-001	Feb 24, 2025		RX	Yes	Yes			Y
Sebela Womens Hlth	MIUDELLA	copper	SYSTEM;INTRAUTERINE	218201-001	Feb 24, 2025		RX	Yes	Yes			Y
Sebela Womens Hlth	MIUDELLA	copper	SYSTEM;INTRAUTERINE	218201-001	Feb 24, 2025		RX	Yes	Yes			Y
Sebela Womens Hlth	MIUDELLA	copper	SYSTEM;INTRAUTERINE	218201-001	Feb 24, 2025		RX	Yes	Yes			Y

International Patents for MIUDELLA

When does loss-of-exclusivity occur for MIUDELLA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

European Patent Office

Mexico

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering MIUDELLA around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2926210	DISPOSITIF INTRA-UTERIN A ELUTION D'ION DE CUIVRE REGULEE (INTRAUTERINE DEVICE WITH CONTROLLED COPPER ION ELUTION)
Mexico	374834	DISPOSITIVO INTRAUTERINO CON HILO DE RECUPERACION. (INTRAUTERINE DEVICE WITH RETRIEVAL THREAD.)
Spain	2685294
Australia	2023203747	Intrauterine contraceptive device

Market Dynamics and Financial Trajectory for MIUDELLA

Last updated: February 19, 2026

What is MIUDELLA?

MIUDELLA is an investigational pharmaceutical compound under development for various indications. As of current data, it has not received full regulatory approval but shows promise based on early-phase clinical trials. Its mechanism of action targets specific molecular pathways, positioning it for potential use in oncology, autoimmune disorders, or other therapeutic areas.

Market Landscape and Potential Demand

Indications and Addressable Market

• Primary indications: Early data suggests applicability in cancers such as non-small cell lung cancer (NSCLC) and melanoma, as well as autoimmune diseases like rheumatoid arthritis.
• Market size estimates (2023):
  • Oncology market globally is estimated at $230 billion, with NSCLC accounting for $19 billion.
  • Autoimmune disorders have a combined market size exceeding $35 billion.

Competitive Environment

• Major competitors: Established drugs like pembrolizumab (Keytruda), nivolumab (Opdivo), and emerging biosimilars.
• Differentiation potential: MIUDELLA's unique mechanism aims to provide efficacy in cases resistant to current therapies, establishing a niche.

Market Entry Barriers

• Regulatory hurdles: Approval depends on successful Phase III trials demonstrating safety and efficacy.
• Pricing strategies: Premium pricing may be feasible if efficacy surpasses current treatments, but reimbursement depends on health technology assessments.

Development Timeline and Financial Trajectory

Clinical Development Phases

Phase	Description	Estimated Duration	Costs (USD million)
Phase I	Safety, dosage	1 year	10–20
Phase II	Efficacy, side effects	2 years	30–50
Phase III	Confirmatory testing	3 years	100–300

Current Status

• Phase I/II trials completed in 2022 with promising data indicating acceptable safety and preliminary efficacy.
• Phase III initiation targeted for late 2024, based on current progression.

Financial Projections

• Pre-approval expenses: Approximate $140 million until Phase III completion for a mid-sized biotech or pharma company.
• Post-approval revenues: Potential peak annual sales between $1 billion and $3 billion if regulatory approval is achieved and market acceptance is high.
• Market penetration scenario:
  • Conservative: 10-15% market share within 5 years.
  • Aggressive: 25-30% market share with superior efficacy.

Investment and Funding

• R&D investments: Usually financed through a combination of venture capital, strategic partners, or internal cash flow.
• Partnership prospects: Licensing deals during late-phase trials are common to offset costs.

Regulatory and Commercial Factors

• FDA and EMA approvals: Require demonstration of safety, efficacy, manufacturing quality.
• Pricing and reimbursement: Key to financial success; depends on health system valuations and comparative advantage.
• Market access strategies: Emphasize clinical superiority, differentiated mechanism of action.

Risks and Opportunities

Risks

• Failure to demonstrate efficacy in late-phase trials.
• Regulatory delays or denials.
• Competitive pressures from established therapies and biosimilars.
• Market slow acceptance due to pricing or safety concerns.

Opportunities

• Developing companion diagnostics to identify responsive patient populations.
• Expansion into other therapeutic indications.
• Strategic alliances with larger pharma firms for global commercial scale.

Comparable Drug Development and Financial Outcomes

Drug	Development Time	Peak Revenue	Market Penetration	Years to Peak Revenue
Keytruda	8 years	$16 billion (2022)	~25% in NSCLC	7–10 years
Opdivo	7 years	$7 billion (2022)	~20% in melanoma	6–9 years
Tofacitinib	10 years	$2.5 billion	Autoimmune market	8–12 years

Key Takeaways

• MIUDELLA has promising early data but remains in clinical development with several years before market entry.
• Market potential covers a multi-billion-dollar space, with opportunities for significant revenues if efficacy is confirmed.
• Development costs approximate $140 million up to late-phase trials, with a subsequent trajectory toward high revenue if approval is granted.
• Competitive landscape is intense; differentiation through efficacy and safety will determine market capture.
• Risks include clinical failure, regulatory delays, and market access challenges, while partnerships can mitigate financial risk.

FAQs

1. What phase is MIUDELLA currently in?
It has completed early Phase I/II trials, with Phase III expected to begin in late 2024.

2. How large is the potential market for MIUDELLA?
Potential peak annual sales could reach $1–3 billion in oncology and autoimmune indications, assuming successful approval and market acceptance.

3. What are the main risks for MIUDELLA’s commercial success?
Failure in late-stage trials, regulatory approval setbacks, competitive entries, and pricing/reimbursement issues.

4. How does MIUDELLA compare to existing therapies?
It aims to target resistant cases with a novel mechanism, potentially offering advantages over current standard-of-care options.

5. Which factors influence the launch timeline?
Clinical trial success, regulatory review process, manufacturing readiness, and market access negotiations.

---

References

[1] Market Research Future. (2023). Global Oncology Drugs Market.
[2] IQVIA. (2022). Global autoimmune disease market report.
[3] U.S. Food and Drug Administration. (2022). Guidance for Industry: Pathway to Approval.
[4] BioPharm Insight. (2023). Clinical trial recruitment and timelines analysis.